

2VAL Study 2010

Status of study: Closed
Name of Study: 2VAL: Two Valine Esters Study
Study Registration: ACTRN12610000016033; CRG090700119
URL to Study Registration: <http://www.anzctr.org.au/ACTRN12610000016033.aspx>

Design: RCT

Included in Reviews	Review Title	Section
Smith, Justin	Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients	Included

Interventions

Valacyclovir
Valganciclovir

Health care conditions

Cytomegalovirus (CMV)
Kidney Transplantation

References

- Kacer M, Kielberger L, Bouda M, Reischig T. Pharmaco-economic impact of valganciclovir versus valacyclovir for cytomegalovirus prophylaxis in renal transplant recipients: A randomized controlled trial [abstract]. *Transplantation*. 2014; 98(Suppl 1) : 763.
- Kacer M, Kielberger L, Bouda M, Reischig T. Valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus: an economic perspective. *Transplant Infectious Disease*. 2015; 17(3) : 334-341.
- Reischig T, et al. Valganciclovir prophylaxis against cytomegalovirus impairs lymphocyte proliferation and activation in renal transplant recipients. *Antiviral Therapy*. 2011; 16(8) : 1227-35.
- Reischig T, Jindra P, Hes O, Lysak D, Bouda M. The 2VAL Study: Randomized comparison of valganciclovir vs. valacyclovir for cytomegalovirus prophylaxis after renal transplantation [abstract no: LB19]. *American Journal of Transplantation*. 2012; 12(Suppl S3) : 361.
- Reischig T, Kacer M, Jindra P, Hes O, Lysak D, Bouda M. Randomized trial of valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation. *Clinical Journal of the American Society of Nephrology: CJASN*. 2015;
- Reischig T, Prucha M, Sedlackova L, Jindra P, Bouda M, Matejovic M. Lymphocyte function during valacyclovir and valganciclovir cytomegalovirus prophylaxis in renal transplant recipients [abstract no: 349]. *American Journal of Transplantation*. 2010; 10(Suppl 4) : 143.